How Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement.
It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then, our team has been hard at work laying the groundwork for the next major chapter in Cytonics’ journey: advancing CYT-108 through the FDA’s regulatory process and into the next phase of clinical development.
If things have seemed a little quiet since our “thank you” message in early September, it’s because the past several weeks have been a whirlwind of behind-the-scenes activity. Here’s a closer look at what’s been happening.
Engaging Experts to Map the Path Forward
Since the close of the offering, Cytonics has brought on a team of specialized regulatory and scientific consultants to conduct a comprehensive review of our preclinical and clinical data package. Their mandate: to develop a detailed “critical path” strategy that will guide our progression through the FDA’s regulatory framework.
This process ensures that our data are not only scientifically sound but also aligned with FDA expectations, setting us up for a smooth transition into the next phase of human trials.
Preparing for a Type C Meeting with the FDA
A key step in this process is the Type C Meeting: a formal meeting with the FDA that allows sponsors to discuss their findings, data, and future development plans directly with agency reviewers.
These meetings serve as a strategic checkpoint in drug development, enabling companies like Cytonics to receive targeted regulatory feedback before launching the next phase of trials. For CYT-108, this meeting will center on our Phase 1 results, preclinical findings, and the proposed design of our upcoming Phase 1b/2a study.
Phase 1 Database Lock and Statistical Review
We’re pleased to report that the Phase 1 database has officially been locked.
Database lock is a major milestone in any clinical program. It means that all patient data have been collected, cleaned, and verified for accuracy. From this point forward, no further changes can be made, allowing our biostatistics team to begin formal data analysis (more on this in a separate post).
The next step is the Clinical Study Report (CSR): the comprehensive document that compiles the study’s methodology, data analyses, and conclusions. The CSR forms the foundation for our upcoming FDA interactions and future regulatory filings.
Looking Ahead: Planning the Next Raise
As we continue advancing toward Phase 1b/2a, we’re also planning for our next capital raise in 2026, which will be designed to fully fund that study through completion. This raise will be conducted at a singificantly higher valuation, representative of the milestones we’ve achieved since August. These inflection points are not just scientific — they’re strategic, paving the way for efficient execution in the next stage of development.
A Note to Our Shareholders
We recognize it’s been a month of “radio silence,” and we appreciate your patience as our team has been fully immersed in these critical next steps. The truth is, it’s been a flurry of activity behind the scenes — and we wanted to make sure that when we spoke next, we had real progress to share.
Our official Q3 2025 investor update, complete with financials and detailed program updates, will be sent out soon.
Thank you to our 8,500+ shareholders for your continued confidence and support. You’re helping us prove that a grassroots biotech — funded by everyday investors, not Venture Capital — can challenge Big Pharma and redefine the future of joint health.
Appreciatively,
Joey Bose
President & CEO
Forward Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the progress of and plans related to the Company’s product candidates, clinical studies and preclinical research and development programs, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress and timelines. These and any other forward-looking statements in this release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Company’s product candidates or in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties in manufacturing or supplying the Company’s product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects, and the risk that the Company may incur operating expenses in amounts greater than anticipated. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission (https://www.sec.gov/edgar/browse/?CIK=0001421744), including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Cytonics Corporation is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
